GSK cervical cancer vaccine gets best response among young girls

12/18/2005 | CNN

A Phase III trial of GlaxoSmithKline's vaccine against the virus that causes cervical cancer showed the immune response was twice as strong for girls aged 10 to 14 than for females 15 to 25, suggesting early vaccination achieves the most prolonged protection. A GSK researcher said the concentration of antibodies to the virus were twice as high in the bloodstreams of young girls compared with older subjects.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide